Allen & Overy advises Exponent on investment in Chanelle Pharma

Published Date
Feb 9, 2024
LONDON – Allen & Overy (A&O) has advised Exponent Private Equity LLP (Exponent), a leading European private equity firm, on its investment in Ireland's largest manufacturer of generic pharmaceuticals, Chanelle Pharma (Chanelle).

Chanelle Pharma manufacturers both medical and veterinary products and is internationally recognised as a leading player in the global generics pharma industry, with a presence in over 80 countries. 

The transaction is the third investment that A&O has supported Exponent on in Ireland and demonstrates A&O’s strength in combining life sciences sector knowledge with private equity and leveraged finance expertise.

The A&O team advising on the transaction was led by private equity partners Chris Sabine and Gordon Milne, senior associates Aoife Mac Dermott and Caroline Crawford, associates Kevin Leitao and Harriet Lister and trainee Craig Shackleton

The multi-disciplinary team from A&O also provided leverage finance advice, led by partner Neil Sinha with senior associates James Green and Dhruv Mairal and associates Fraser Jackson and Jack Cameron. Tax advice was provided by partner Tim Harrop and senior associate Michael Fletcher, with anti-trust advice from senior associate David Weaver and associate Amol Vani.

The deal is subject to Competition and Consumer Protection Commission approval.

Content Disclaimer
This content was originally published by Allen & Overy before the A&O Shearman merger